Metabolomics

Biosfer Teslab invited in the first Futurecamp Open Future, eHealth & Wellbeing

Last 23rd and 24th November, our Quality Manager Sara Samino, participated in the first Futurecamp Open Future, eHealth & Wellbeing together with 5 other start-ups in the sector organized by Telefonica Open Future. Last year, Biosfer Teslab was selected to participate in the Tarragona Open Future where it was awarded with the second place. Open… Read More »Biosfer Teslab invited in the first Futurecamp Open Future, eHealth & Wellbeing

Biosfer Teslab invitada en el primer Futurecamp Open Future

Metabolomics arrives at “The liver Meeting” comes from Biosfer Teslab

From 12 to 15 November took place the “The liver Meeting” organised by the American Association for the Study of Liver Diseases (AASLD). The mission of the association is to advance and disseminate the science and practice of hepatology, and to promote liver health. This year, Biosfer Teslab, together with OWL Metabolomics, University of Medicine… Read More »Metabolomics arrives at “The liver Meeting” comes from Biosfer Teslab

Metabolòmica al the Liver meeting

Early molecular signature of Parkinson and dementia years before the diseases appear

NMR metabolomics could identify altered lipoprotein and protein glycosylation profiles in REM sleep behavior disorder (iRBD), the prodromal stage of Lewy-type synucleinopathies (LTS) -including Parkinson and dementia. NMR showed predictive power distinguishing future clinical outcome, being a useful tool for identifying short-term high-risk patients for conversion to parkinsonism or dementia. Here you can see the… Read More »Early molecular signature of Parkinson and dementia years before the diseases appear

Nuclear magnetic resonance-based metabolomic analysis in the assessment of preclinical atherosclerosis in type 1 diabetes and preeclampsia

Dr. Amor and collaborators have published a new article in the Diabetes Research and Clinical Practice journal using our plasma metabolomics analysis. The aim of the study was to evaluate the role of plasma metabolomics in atherosclerosis according to the presence of type 1 diabetes (T1D) or previous preeclampsia. They have concluded that plasma metabolomics… Read More »Nuclear magnetic resonance-based metabolomic analysis in the assessment of preclinical atherosclerosis in type 1 diabetes and preeclampsia

Metabolomics Reveals Reduction of Metabolic Oxidation in Women with Polycystic Ovary Syndrome after Pioglitazone-Flutamide-Metformin Polytherapy

Abstract Polycystic ovary syndrome (PCOS) is a variable disorder characterized by a broad spectrum of anomalies, including hyperandrogenemia, insulin resistance, dyslipidemia, body adiposity, low-grade inflammation and increased cardiovascular disease risks. Recently, a new polytherapy consisting of low-dose flutamide, metformin and pioglitazone in combination with an estro-progestagen resulted in the regulation of endocrine clinical markers in… Read More »Metabolomics Reveals Reduction of Metabolic Oxidation in Women with Polycystic Ovary Syndrome after Pioglitazone-Flutamide-Metformin Polytherapy

From LAB to market

Last year we published 19 scientific articles in international journals. We are a metabolomics company halfway between research and clinical practice, a scientific research group in a business environment that is committed to translational research. We carry out scientific collaborations with research groups from universities, research institutions, hospitals and companies in the biomedical sector both… Read More »From LAB to market

Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles

Our lipoprotein profile, Liposcale (CE), in Cardiovascular Diabetology: “Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles” The research groups of Sant Pau and Hospital Clinic lead by Dr. Didac Mauricio, Dr. Emilio Ortega and Dr. Antonio Amor have published a relevant study including more than 500 type 1 Diabetic… Read More »Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles

Predicting the future of health

Once infected by SARS-CoV-2, would you like to know your health status evolution?   This is Biosfer Teslab commitment in the SARS-CoV-2 pandemic. The Spanish Institute of Health Research Pere Virgili, Fundación Alcorcón University Hospital, SCIENCE&STRATEGY SL, Laboratorios Rubió SA, and Biosfer Teslab together with Treat systems (Denmark), Kinesys Consulting (UK), EuroCrime (Italy) have built… Read More »Predicting the future of health